Eli Lilly: study shows efficacy of psoriatic arthritis drug

(CercleFinance.com) - A drug made by Eli Lilly showed "robust and consistent" efficacy in patients with psoriatic arthritis, the drugmaker said on Wednesday.


According to new results from a Phase 3b/4 trial a higher proportion of patients treated with Lilly's Taltz achieved "minimal disease activity" compared to AbbVie's Humira in the monotherapy subgroup (49% versus 33%), while response rates were similar.

In addition, more Taltz patients achieved the primary endpoint of simultaneous achievement of at least a 50% improvement in disease activity and 100% improvement in the psoriasis area and severity index at week 52, Lilly said.

These results will be presented virtually on 5 June at the 2020 European Congress of Rheumatology (EULAR).

Copyright (c) 2020 CercleFinance.com. All rights reserved.